28 October 2026
What does it take to make research and healthcare more equitable for people who use drugs? At INHSU 2026, speakers challenged traditional approaches to community involvement, explored the health consequences of stigma and called for services that better reflect people’s lived realities.
Here, we revisit four presentations that highlight why meaningful change requires listening to people who use drugs and giving them a greater say in the decisions that affect their health.
Putting people who use drugs in control of research
Including people who use drugs in research is not the same as giving them genuine power over how evidence is produced and used.
In Beyond Participation: Leadership of People Who Use Drugs in Research and Evidence Generation, Dr Annie Madden, Project Lead at the International Network of People Who Use Drugs (INPUD), challenged traditional approaches to community involvement in research.
While people who use drugs are increasingly included in research, academic institutions often retain control over which questions are asked, what counts as credible evidence and how findings are interpreted.
Madden argued that meaningful community leadership requires more than participation. It means recognising the expertise people who use drugs already hold, rather than expecting them to become professional researchers before their knowledge is considered valuable.
It also means giving communities the resources and authority to set their own research priorities, generate and interpret evidence, and decide how that evidence is used to drive change.
Madden challenged researchers to rethink where they begin:
Stop starting with the question, ‘How can we involve community in our research?’ and start asking, ‘What does community need to know, and what evidence do they want to produce?’
What does stigma reduction actually look like inside an AOD service?
In the plenary orals, Professor Loren Brener from the Centre for Social Research in Health at UNSW Sydney presented findings from interviews with 37 lived and living experience workers employed across Australian AOD services.
Workers described shame as pervasive among people accessing services, affecting self-worth, willingness to disclose substance use and engagement with care. The research found that stigma can also be reinforced in less obvious ways through language, relationships, power dynamics and routine service practices.
“Shame is a key way stigma can become internalised, affecting people’s self-worth, willingness to disclose substance use, seek support and remain engaged with care. It can be produced and reinforced through social judgement, language and power dynamics within services,” said professor Brener.
The research also explored the role lived and living experience workers can play in challenging those dynamics. Participants described using non-judgemental engagement, shared understanding, self-disclosure and careful language to reduce shame and build trust.
I’d love to see workers with lived and living experience embedded and genuinely valued across AOD and harm reduction services, not simply for the rapport they can build, but for the expertise and insight their experience brings to understanding and reducing stigma and shame.
Stigma is associated with injection-related bacterial infections
Dr Adelina Artenie from the University of Montreal presented research examining the relationship between substance use-related stigma and injection-related bacterial infections among 377 people who inject drugs in Montréal.
The study used the Substance Use Stigma Mechanisms Scale, a validated tool that separates stigma into three mechanisms: enacted (past experiences of discrimination), anticipated (expectations of future discrimination) and internalised (applying negative societal beliefs about drug use to oneself). For enacted and anticipated stigma, it also distinguishes whether the source is family members or healthcare workers.
“In other words, we looked at how people are treated by others, how they expect to be treated, and how they see themselves, and whether this shows up in their health,” said Dr Artenie.
Almost one in four participants reported an injection-related bacterial infection in the previous three months. These infections can range from skin abscesses to serious infections of the blood, bones and heart.
Enacted stigma showed the clearest relationship with infection.
In our study, enacted stigma showed the clearest link: people reporting high levels were twice as likely to report a recent injection-related bacterial infection.
Dr Artenie.
One finding particularly surprised Artenie.
Family was a bigger source of stigma than healthcare. About 3 in 10 people reported high enacted stigma from family, compared with about 1 in 10 from healthcare workers.
Artenie said the findings could broaden where stigma-reduction efforts are directed. Alongside training for healthcare workers, she would like to see greater support and education for families and further research into other sources of stigma, including police and the wider community.
Women who use drugs need services designed around their lives
Women who use drugs face overlapping health and social challenges, yet many remain underserved by existing health systems.
In Understanding Drug Use Among Women: Epidemiology and Syndemics of Trauma, Mental Health, Gender-based Violence, and Infection, Professor Anna Mia Ekström, Karolinska Institutet, explored how HIV, viral hepatitis, violence, criminalisation and stigma intersect to shape women’s health and their access to care.
These challenges are becoming increasingly urgent as funding cuts threaten HIV prevention and harm reduction services, particularly in countries reliant on international aid. Women who use drugs, already among the populations least reached by health systems, risk becoming even more marginalised.
“Instead of expecting women to fit existing services, we need to design services around women’s realities,” said Professor Ekström.
Ekström called for sustainable investment in integrated, gender-responsive services that bring together harm reduction, HIV and hepatitis care with sexual and reproductive health, responses to violence and legal support.
Crucially, women with lived experience must be central to designing these services, rather than being expected to navigate systems that fail to reflect their needs.
Listen to women who use drugs—and act on what they tell us. Ask whether our services truly reach women, meet their various needs, protect their dignity and safety, and respond to their real lives.

